DAYANG BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 80.366 million yuan, an increase of 56.12%

DAYANG BIOTECH released its Q3 2025 report, with operating revenue for the first three quarters amounting to 747 million yuan, a year-on-year increase of 11.24%. The net profit attributable to the parent company was 80.0366 million yuan, a year-on-year increase of 56.12%. The net profit after deducting non-recurring gains and losses was 74.9836 million yuan, a year-on-year increase of 55.61%. The basic earnings per share were 0.9846 yuan

DAYANG BIOTECH issued a preliminary increase, expecting the net profit attributable to the parent company for the first three quarters to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%

DAYANG BIOTECH expects the net profit attributable to the parent company for the first three quarters of 2025 to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%. The net profit after deducting non-recurring gains and losses is expected to be between 67 million yuan and 82 million yuan, a year-on-year increase of 39.04% to 70.17%. The growth in performance is mainly driven by market demand, with sales and prices of the main products, potassium carbonate and veterinary raw materials, rising, leading to an increase in gross profit margin

The A-share chemical and chemical engineering sector fluctuated and strengthened, JJKJ hit the daily limit, DAYANG BIOTECH rose over 5%, JSAC, LIER CHEMICAL, and Yangnong Chemical followed suit

DAYANG BIOTECH: In the first half of the year, the net profit attributable to the parent company was 50.5056 million yuan, a year-on-year increase of 60.66%

On August 25th, DAYANG BIOTECH disclosed its semi-annual report, stating that the company achieved operating revenue of 499 million yuan in the first half of the year, a year-on-year increase of 14.20%; the net profit attributable to shareholders of the listed company was 50.5056 million yuan, compared to 31.4363 million yuan in the same period last year, a year-on-year increase of 60.66%; the basic earnings per share were 0.6212 yuan

DAYANG BIOTECH: The Zhejiang Regulatory Bureau has taken corrective measures against the company's shareholder Yang Xingli and his concerted actors

DAYANG BIOTECH announced that the Zhejiang Regulatory Bureau has taken corrective measures against shareholder Yang Xingli and his concerted actors. After Yang Xingli held more than 5% of the shares, his concerted actors failed to promptly notify the company of their 1% increase in shareholding, violating relevant acquisition management regulations